This latest update presents critical developments in myeloma treatment appraisals by NICE and the SMC.
Stay informed about the latest recommendations, appeal hearings, and upcoming assessments shaping the treatment options for patients and healthcare professionals.
Myeloma UK’s Clinical Service Excellence Programme (CSEP) team revealed insights from their survey entitled ‘Just one thing HCPs would change’ at two international conferences last year.
The data was presented ICCN 2023 in Glasgow and at the 2023 IMS 20th annual meeting and exposition in Athens. Read more to find out the ‘one thing’ healthcare professionals would change to improve their clinical service.
Five exceptional hospitals have been awarded the prestigious CSEP accreditation, recognising their outstanding contributions to myeloma care.
Explore some of the outstanding achievements and highlights that showcase these hospitals’ commitment to exceptional patient care.
Have you heard about our free Myeloma UK publication dispensers for hospitalst? Already used in 84 hospitals around the UK to display our patient information publications, they come in two designs to suit the space. Read more and find out how to order your dispenser.
As the anticipation for ASH 2023 builds, Professor Graham Jackson, consultant haematologist and Myeloma UK’s Chief Clinical and Scientific Advisor, sheds light on the top abstracts to watch, offering a curated glimpse into the forefront of myeloma research.
New research has uncovered a concerning gap in the time taken to diagnose myeloma between ethnic groups, with black people experiencing longer waits for a diagnosis than white people. The study showed that black patients diagnosed with myeloma had a median wait time of over one month longer than white people.
This important virtual national conference provides an essential update for current and aspiring non medical prescribers on prescribing at the end of life. It is widely recognized that pain and symptom control at the end of life is not always optimal, the development of non medical prescribing has a key role in improving pain and…
Results from two phase III clinical trials (MAIA and CASSOPIEA) evaluating daratumumab (Darzalex®) combinations for the treatment of newly diagnosed myeloma patients have been recently published. The data provide evidence to support the use of daratumumab for the treatment of newly diagnosed myeloma patients whether they are eligible for high dose therapy and stem cell…
The Myeloma Diagnosis Pathway is an easy to follow, quick reference tool to help GPs and other healthcare professionals recognise the signs and symptoms of myeloma. It provides information on which tests and investigations should be conducted before referral to a haematologist. It has been designed by Myeloma UK and reviewed by a working group…
